Home > > Global Liquid Biopsy Market Report
The Liquid Biopsy market was valued at $7,577.3 Million in 2022, and is projected to reach $32,071.9 Million by 2032 growing at a CAGR of 15.59% from 2023 to 2032.A liquid biopsy is a diagnostic test that uses a sample of blood or other body fluid to detect the presence of cancer or other diseases. It is a non-invasive alternative to traditional biopsy procedures, which involve the removal of tissue samples for laboratory analysis. Some of the key drivers of the liquid biopsy market include the increasing prevalence of cancer, the growing demand for minimally invasive diagnostic procedures, and the availability of advanced technologies such as next-generation sequencing. There are several companies that are active in the liquid biopsy market, including: Guardant Health: Guardant Health is a leading provider of liquid biopsy tests for the early detection and monitoring of cancer. The company's flagship product, Guardant360, is a comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) to detect cancer and track disease progression. Foundation Medicine: Foundation Medicine is a leading provider of genomic profiling and liquid biopsy tests for cancer patients. The company's liquid biopsy test, FoundationOne Liquid, analyzes ctDNA to identify genomic alterations that may be driving a patient's cancer. QIAGEN: QIAGEN is a global leader in sample and assay technologies, including liquid biopsy tests. The company's liquid biopsy platform, QIAsure, uses circulating tumor cells (CTCs) to detect cancer and monitor treatment response. Roche: Roche is a global pharmaceutical company with a strong presence in the liquid biopsy market. The company offers a range of liquid biopsy tests, including the cobas EGFR Mutation Test, which detects epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients. Illumina: Illumina is a leading provider of genomic sequencing and analysis technologies, including liquid biopsy tests. The company's liquid biopsy platform, Veracyte, uses ctDNA analysis to detect cancer and track disease progression. In recent years, these companies have made significant progress in the development of liquid biopsy technologies and products. For example, Guardant Health has received FDA approval for its liquid biopsy test for the early detection of lung cancer, and Foundation Medicine has announced the development of a liquid biopsy test for the early detection of pancreatic cancer. Similarly, QIAGEN has expanded its liquid biopsy portfolio with the launch of several new products, and Roche has announced the development of a liquid biopsy test for the detection of KRAS gene mutations in colorectal cancer.